177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer
Latest Information Update: 22 May 2025
At a glance
- Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary) ; Olaparib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Acronyms LuPARP
Most Recent Events
- 14 May 2025 Status changed from recruiting to active, no longer recruiting.
- 03 May 2024 Planned number of patients changed from 52 to 70.
- 03 May 2024 Planned End Date changed from 1 Dec 2023 to 1 Jun 2026.